for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Albireo Pharma Inc

ALBO.OQ

Latest Trade

17.74USD

Change

-0.33(-1.83%)

Volume

10,527

Today's Range

17.74

 - 

18.29

52 Week Range

16.26

 - 

38.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
18.07
Open
18.06
Volume
10,527
3M AVG Volume
1.13
Today's High
18.29
Today's Low
17.74
52 Week High
38.48
52 Week Low
16.26
Shares Out (MIL)
12.69
Market Cap (MIL)
223.39
Forward P/E
-3.03
Dividend (Yield %)
--

Latest Developments

More

Albireo Pharma Q2 Loss Per Share $1.35

Albireo Provides Mid-Year Clinical Development Update

Albireo Pharma Reports Q1 Loss Per Share Of $1.39

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Albireo Pharma Inc

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company's pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

Industry

Biotechnology & Drugs

Contact Info

10 Post Office Square, Suite 502 South

+1.857.4154774

http://www.albireopharma.com/

Executive Leadership

David Chiswell

Independent Chairman of the Board

Ronald Harold Wilfred Cooper

President, Chief Executive Officer, Director

Simon N.R. Harford

Chief Financial Officer, Treasurer

Jan P. Mattsson

Chief Scientific Officer

Martha J. Carter

Chief Regulatory Officer

Key Stats

1.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2017

-3.150

2018

-3.940

2019(E)

-5.921
Price To Earnings (TTM)
--
Price To Sales (TTM)
85.00
Price To Book (MRQ)
1.90
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-34.48
Return on Equity (TTM)
-32.73

Latest News

Latest News

BRIEF-Albireo Qtrly Net Loss Per Share - Basic And Diluted $0.15

* ALBIREO PHARMA INC - QTRLY NET LOSS PER SHARE - BASIC AND DILUTED $0.15 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Albireo Enrolls First Patient In Phase 3 PFIC Trial Of A4250

* ALBIREO ENROLLS FIRST PATIENT IN PHASE 3 PFIC TRIAL OF A4250 Source text for Eikon: Further company coverage:

BRIEF-Albireo Pharma Inc Files For Non-Timely 10-K

* ALBIREO PHARMA INC FILES FOR NON-TIMELY 10-K WITH THE U.S. SEC Source text: (http://bit.ly/2pobWiJ) Further company coverage:

BRIEF-Albireo Reports Fourth Quarter And Year-End 2017 Financial Results

* ALBIREO REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

BRIEF-Albireo Prices $65.0 Mln Public Offering Of Common Stock

* ALBIREO PRICES $65.0 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Albireo Pharma Says Elobixibat Approved In Japan For Treatment Of Chronic Constipation

* ALBIREO TO RECEIVE MORE THAN $55 MILLION(1) IN NONDILUTIVE CASH PAYMENTS

BRIEF-Albireo Announces Agreement With Healthcare Royalty Partners

* ALBIREO ANNOUNCES ROYALTY MONETIZATION AGREEMENT WITH HEALTHCARE ROYALTY PARTNERS FOR ELOBIXIBAT IN JAPAN

BRIEF-Albireo posts Q3 loss per share $0.73

* Albireo Pharma Inc - decision on potential approval of elobixibat in Japan expected in first half of 2018

BRIEF-Albireo Pharma to present final results of phase 2 study of A4250 in children with cholestatic liver disease

* Final results of Albireo’s phase 2 study of A4250 in children with cholestatic liver disease presented at the liver meeting 2017

BRIEF-Albireo Pharma files for mixed shelf of up to $125 million

* Albireo Pharma Inc files for mixed shelf of up to $125 million - SEC filing Source text for Eikon: (http://bit.ly/2i8yKC7) Further company coverage:

BRIEF-Albireo elects Roger Jeffs to board of directors

* Albireo Pharma Inc - Jeffs replaces Denise Scots-Knight, who is departing from board Source text for Eikon: Further company coverage:

BRIEF-EMA paediatric committee agrees to Albireo's A4250 pediatric investigation plan

* EMA's paediatric committee agrees to Albireo’s a4250 pediatric investigation plan

BRIEF-Albireo Pharma Q2 loss per share $0.86

* Albireo Pharma Inc - qtrly net loss per share diluted $0.86

BRIEF-Albireo Pharma files non-timely 10-K

* Albireo Pharma - unable to file 10-Q quarter ended June 30, 2017 in time due to unexpected delay in preparation of unaudited interim financial statements

BRIEF-Perceptive Advisors LLC reports 9.93 pct passive stake in Albireo Pharma as of May 24 - Sec Filing

* Perceptive Advisors LLC Reports 9.93 Pct Passive Stake In Albireo Pharma Inc as of May 24 - Sec Filing Source text for Eikon: Further company coverage:

BRIEF-Muneer Satter reports 9.77 pct passive stake in Albireo Pharma

* Muneer A. Satter reports 9.77 percent passive stake in Albireo Pharma Inc as of May 24, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2rkJUWZ) Further company coverage:

BRIEF-Albireo prices $45.1 million public offering of common stock

* Albireo prices $45.1 million public offering of common stock

BRIEF-Albireo reports proposed public offering of common stock

* Albireo announces proposed public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Albireo Pharma reports Q1 loss per share $1.06

* Qtrly loss per share $1.06 Source text for Eikon: Further company coverage:

BRIEF-Albireo reports 2016 financial results

* Expects that its current cash resources will be sufficient to meet its operating requirements at least through mid 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up